Literature DB >> 23238629

Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors.

Asli Yilmaz1, Tina Cheng, Jianguo Zhang, Kiril Trpkov.   

Abstract

Clinical staging is a critical step in the management of testicular germ cell tumors. Up to one-third of nonseminomatous germ cell tumors of the testis present with metastatic disease (clinical stages II and III). We investigated the predictors of metastatic disease at presentation in a cohort of 148 consecutive nonseminomatous germ cell tumors of the testis, over a 10-year period. The following clinical and pathologic features were evaluated: age, tumor size, dominant tumor histology, coagulative necrosis, vascular invasion, rete testis invasion and tumor extension into tunica vaginalis, hilar soft tissue, epididymis, or spermatic cord. Studied parameters were correlated with the clinical stage at presentation. Of the 148 patients with nonseminomatous germ cell tumors of the testis, 94 (63%) were clinical stage I, 26 (18%) were stage II, and 28 (19%) were stage III at presentation. Mean patient age was 31 years (range, 17-83). Mean tumor size was 4.1 cm (range, 0.6-19). On univariate analysis, the following parameters showed statistically significant association with the advanced clinical stage at presentation: vascular invasion (P<0.001), rete testis invasion (P<0.001), hilar soft tissue invasion (P<0.001), epididymis invasion (P=0.005), spermatic cord invasion (P=0.005), and coagulative necrosis (P=0.062). On multivariate analysis, only vascular invasion (P=0.011) and invasion into the rete testis and the hilar soft tissues (P=0.007 and P=0.017, respectively) demonstrated significant association with advanced clinical stage at presentation. We conclude that in addition to vascular invasion, tumor invasion into the hilum (rete testis or hilar soft tissue) is also strongly associated with metastatic disease at presentation and should be part of the routine pathology reporting.

Entities:  

Mesh:

Year:  2012        PMID: 23238629     DOI: 10.1038/modpathol.2012.189

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Testicular germ cell tumors: the changing role of the pathologist.

Authors:  Andrea Ronchi; Francesca Pagliuca; Renato Franco
Journal:  Ann Transl Med       Date:  2019-09

2.  Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists.

Authors:  Daniel M Berney; Ferran Algaba; Mahul Amin; Brett Delahunt; Eva Compérat; Jonathan I Epstein; Peter Humphrey; Mohammed Idrees; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Gregor Mikuz; Rodolfo Montironi; Esther Oliva; John Srigley; Victor E Reuter; Kiril Trpkov; Thomas M Ulbright; Murali Varma; Clare Verrill; Robert H Young; Ming Zhou; Lars Egevad
Journal:  Histopathology       Date:  2015-03-17       Impact factor: 5.087

3.  Total embedding of spermatic cord and hilar soft tissue in orchiectomy for seminoma: does the extensive sampling improve pathologic risk factors?

Authors:  Maurizio Colecchia; Biagio Paolini; Giacomo Maria Pini; Laura Carpenito; Beatrice Maghini; Barbara Avuzzi; Anna Maria Paganoni; Nicola Nicolai
Journal:  Virchows Arch       Date:  2022-07-01       Impact factor: 4.064

Review 4.  [Testicular tumours from a clinical point of view : What urologists and oncologists need to know from the pathologist about testicular cancer].

Authors:  Christoph Oing; Christian Daniel Fankhauser
Journal:  Pathologie (Heidelb)       Date:  2022-09-26

Review 5.  [What does the oncologist need from the pathologist in testicular cancer?]

Authors:  Christoph Oing; Mia-Carlotta Peters; Felix Bremmer
Journal:  Pathologe       Date:  2020-12       Impact factor: 1.011

6.  Hypermethylation of genes in testicular embryonal carcinomas.

Authors:  Hoi-Hung Cheung; Yanzhou Yang; Tin-Lap Lee; Owen Rennert; Wai-Yee Chan
Journal:  Br J Cancer       Date:  2015-12-01       Impact factor: 7.640

7.  SPANXN2 functions a cell migration inhibitor in testicular germ cell tumor cells.

Authors:  Fang Zhu; Hao Bo; Guangmin Liu; Ruixue Li; Zhizhong Liu; Liqing Fan
Journal:  PeerJ       Date:  2020-06-23       Impact factor: 2.984

8.  Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.

Authors:  João Lobo; Ad J M Gillis; Annette van den Berg; Leendert H J Looijenga
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.